Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Medicus Pharma Ltd ( (MDCX) ) is now available.
Medicus Pharma has received U.S. FDA clearance to proceed with a Phase 2b dose-optimization study of its investigational GnRH antagonist Teverelix in men with advanced prostate cancer who are appropriate for androgen deprivation therapy. The open-label trial will enroll 40 patients and aims to confirm rapid and durable testosterone suppression with a high probability of achieving medical castration by Day 29 and maintaining it through Day 155.
The company is positioning Teverelix as a potentially best-in-class hormone therapy for advanced prostate cancer patients with objectively defined high cardiovascular risk, differentiating it from GnRH agonists that may worsen cardiovascular outcomes. Study results are intended to support a registrational Phase 3 program and a cardiovascular risk–focused labeling strategy, which could make Teverelix a new therapeutic backbone in a U.S. market opportunity exceeding US$4 billion for this patient segment.
The most recent analyst rating on (MDCX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and heavy cash burn with negative equity) and bearish technicals (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend support, while recent financing provides some liquidity benefit but reinforces dilution/financing dependence.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a precision-guided biotech and life sciences company focused on developing novel, potentially disruptive therapeutic assets. Its lead program centers on Teverelix, a next-generation long-acting GnRH antagonist targeting advanced prostate cancer patients with high cardiovascular risk and acute urinary retention relapse prevention, markets estimated at about US$6 billion combined.
Average Trading Volume: 323,027
Technical Sentiment Signal: Sell
Current Market Cap: $28.36M
See more data about MDCX stock on TipRanks’ Stock Analysis page.